Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Malacoplasma iowae 695

ABSTRACT: Malacoplasma iowae 695 Genome sequencing

PROVIDER: PRJNA503681 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other
	SRR20006035_subreads.fastq.gz	Fastqsanger.gz

Items per page:

1 - 2 of 2

Similar Datasets

Malacoplasma iowae 695

Project description:Malacoplasma iowae 695 Genome sequencing and assembly

| PRJNA68271 | ENA

Malacoplasma iowae

Project description:Mycoplasma iowae overview

| PRJNA68407 | ENA

Malacoplasma iowae DK-CPA

Project description:Malacoplasma iowae DK-CPA Genome sequencing and assembly

| PRJNA217423 | ENA

Xanthomonas euvesicatoria strain:695

Project description:Xanthomonas euvesicatoria strain 695 Genome sequencing

| PRJNA275505 | ENA

Cronobacter sakazakii strain:695

Project description:Cronobacter sakazakii strain:695 Genome sequencing and assembly

| PRJNA251799 | ENA

Caulobacter radicis strain:695

Project description:Caulobacter radicis strain:695 Genome sequencing and assembly

| PRJNA451533 | ENA

Complete Genome Sequence and Annotation of Malacoplasma iowae Type Strain 695, Generated Using PacBio Sequencing.

Project description:Malacoplasma iowae, previously known as "Mycoplasma iowae," is associated with embryo mortality, reduced hatchability, and leg abnormalities in turkeys, leading to considerable economic losses. Here, we report the complete and annotated genome sequence of Malacoplasma iowae type strain 695.

| S-EPMC9872633 | biostudies-literature

INCREASED HEAT SHOCK PROTEIN 70 EXPRESSION BY CM-695 ASSOCIATES WITH STRONG ANTITROMBOTIC EFFECT WITHOUT INCREASING BLEEDING

Project description:BACKGROUND Antithrombotic medications target coagulation factors. Their use is associated with an increased bleeding risk. Safer drugs are needed. We described that the heat shock protein 70 (Hsp70) exhibits antithrombotic properties that do not influence bleeding. OBJECTIVES By using murine models, we want to test the hypothesis that overexpressing Hsp70 with CM-695, a dual inhibitor of HDAC6 and phosphodiesterase 9, protects against thrombosis while leaves bleeding tendency unaltered. METHODS CM-695 was used to induce Hsp70 overexpression. Hsp70 overexpressing mice were submitted to three thrombosis-triggering procedures. The ferric chloride carotid artery model was used to compare the antithrombotic role of CM-695 and rivaroxaban, a direct oral anticoagulant. The mouse tail transection model was used to compare the bleeding tendency upon CM-695 or rivaroxaban administration. RESULTS Intraperitoneal (i.p.) 20 mg/kg CM-695 increased Hsp70 expression markedly in the murine aortic tissue. This treatment delayed thrombosis in the collagen/epinephrine [P=0.04 (Log-Rank test), n=10], Rose Bengal/laser [median vessel occlusion time (OT): 58.6 vs. 39.0 minutes (min) in the control group (CG), P=0.008, n≥10] and ferric chloride (OT: 14.7 vs. 9.2 min in the CG, P=0.032, n≥10) models. I.p. 80 mg/kg CM-695 (n≥9) and intravenous 3 mg/kg rivaroxaban (n≥8) significantly delayed thrombosis. CM-695 did not induce bleeding [median bleeding time (BT): 8.5 vs. 7.5 min in the CG, n≥10]. However, this was dramatically increased by rivaroxaban (BT: 30.0 vs. 13.7 min in the CG, P=0.001, n=10). CONCLUSIONS CM-695 is a new antithrombotic drug devoid of bleeding risk that may be envisioned as a useful clinical tool.

2020-01-13 | GSE93958 | GEO

Xanthomonas phaseoli pv. dieffenbachiae LMG 695

Project description:Xanthomonas phaseoli pv. dieffenbachiae LMG 695 Genome sequencing

| PRJNA232101 | ENA

Zea mays cultivar:RSQ-695

Project description:Zea mays RSQ-695 Transcriptome

| PRJNA493423 | ENA